PharmaCyte Biotech, Inc. PMCB
0.40 USD 0.00 (-1.20%)
At closeNov 10, 2026, 4:36 PM EST
0.40 0.00 -0.52%
After hours · Nov 10, 4:36 PM ET
0.3801 Day range 0.4144
0.3021 52-week range 1.51
- YTD
- -44.46%
- 1 year
- -54.31%
News
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers MaxCyte (NASDAQ:MXCT) stock increased by 21.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $130.0 million. Vir Biotechnology (NASDAQ:VIR)…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Onconetix (NASDAQ:ONCO) stock increased by 10.3% to $1.14 during Friday's after-market session. The market value of their outstanding shares is at $3.9 million. Bullfrog AI Hldgs…
benzinga.com PharmaCyte Biotech Q1 EPS $(0.54) Up From $(1.23) YoY, Sales $0.00, Same YoY PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly losses of $(0.54) per share. This is a 56.1 percent increase over losses of $(1.23) per share from the same period last year. The company reported…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com PharmaCyte Biotech Receives Noncompliance Notice From Nasdaq; Has Until June 2026 To Regain Compliance On December 1, 2025, PharmaCyte Biotech, Inc. (the "Company") received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Autodesk Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com PharmaCyte Biotech Monetizes Femasys Stake; Cash And Securities Expected At ~$20M After Monetization, Up From $13.3M PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ:FEMY), further validating the Company's…- benzinga.com PharmaCyte Biotech Q1 EPS $(1.23) Down From $1.90 YoY PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly losses of $(1.23) per share. This is a 164.74 percent decrease over earnings of $1.90 per share from the same period last year.
- benzinga.com PharmaCyte Biotech Invests Additional $3M In TNF Pharmaceuticals To Support LightSolver Partnership TNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner's 2025 Hype Cycle for Data Center Infrastructure TechnologiesPharmaCyte Biotech,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com PharmaCyte Biotech Q4 EPS $1.54 Up From $(0.33) YoY PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly earnings of $1.54 per share. This is a 566.67 percent increase over losses of $(0.33) per share from the same period last year.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com PharmaCyte Biotech Makes $7M Investment In MyMD Pharmaceuticals; Investment In Life Sciences Solidifies Previously Announced Strategy To Utilize Significant Cash Position To Create Additional Stockholder Value Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder valuePharmaCyte Biotech, Inc. (NASDAQ:PMCB)…- benzinga.com PharmaCyte Biotech Acquires $5M Stake In Emerging Women's Health Innovator Femasys, Inc. New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder valuePharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company")…
- benzinga.com PharmaCyte Biotech Provides Corporate Update On Cell-In-A-Box Technology Company prepares for comprehensive discussion with FDA to determine appropriate next steps for technology while evaluating additional opportunitiesPharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte"…
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 369 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 386 stocks made new 52-week lows.- benzinga.com Pancreatic Cancer Action Network Urges Advocates From All 50 States To Call On Congress To Increase Federal Funding For Pancreatic Cancer Research Federal Funding Increases Fuel Research Progress and Help Improve Patient OutcomesLOS ANGELES, June 14, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com PharmaCyte Biotech Announces Cash Tender Offer For Up To 7.75M Shares At $3.25 Per Share Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the
- benzinga.com PharmaCyte Biotech Board Of Directors Announces Business Review Committee To Evaluate Opportunities To Optimize Shareholder Value; CEO Kenneth L. Waggoner Has Stepped Down From The Position As CEO Effective October 6, Joshua N. Silverman As Interim CEO LAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), a biotechnology company focused on evaluating its signature live-cell encapsulation
- benzinga.com PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation https://pharmacyte.com/pharmacyte-biotech-rebukes-iroquois-commencement-of-consent-solicitation/
- benzinga.com PharmaCyte Biotech Reports Interim Results in Malignant Ascites Mouse Model Study PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation…
- benzinga.com PharmaCyte Biotech Announces Additional Quality Control Assay And Confirms Stability Of CypCap Cells PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation…
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021 - benzinga.com 60 Biggest Movers From Friday Gainers
- benzinga.com 41 Stocks Moving In Friday's Mid-Day Session Gainers
- benzinga.com 25 Stocks Moving in Monday's Pre-Market Session Gainers
benzinga.com 58 Biggest Movers From Yesterday Gainers- benzinga.com 38 Stocks Moving In Thursday's Mid-Day Session Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares jumped 141% to $1.7950 after dropping 12% on Wednesday. Sonnet BioTherapeutics recently reported its financial results for the…
- benzinga.com 78 Biggest Movers From Friday Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering.
- benzinga.com 77 Biggest Movers From Yesterday Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares surged 65.4% to close at $2.10 on Thursday after the company announced it is expanding its blockchain business to engage in…
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday
- benzinga.com Stocks That Hit 52-Week Highs On Thursday
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday